C4 Therapeutics Inc - Asset Resilience Ratio
C4 Therapeutics Inc (CCCC) has an Asset Resilience Ratio of 53.03% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how C4 Therapeutics Inc's Asset Resilience Ratio has changed over time. Check CCCC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down C4 Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see C4 Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $174.40 Million | 53.03% |
| Total Liquid Assets | $174.40 Million | 53.03% |
Asset Resilience Insights
- Very High Liquidity: C4 Therapeutics Inc maintains exceptional liquid asset reserves at 53.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
C4 Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare C4 Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for C4 Therapeutics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for C4 Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.44% | $173.93 Million | $359.07 Million | -5.74pp |
| 2024-12-31 | 54.18% | $189.41 Million | $349.60 Million | +20.42pp |
| 2023-12-31 | 33.76% | $127.09 Million | $376.45 Million | -23.43pp |
| 2022-12-31 | 57.19% | $246.40 Million | $430.84 Million | +11.18pp |
| 2021-12-31 | 46.01% | $233.16 Million | $506.76 Million | -1.47pp |
| 2020-12-31 | 47.47% | $189.96 Million | $400.14 Million | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more